CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, published by Wiley, is a premier scholarly journal in the fields of gastroenterology, hepatology, and pharmacology. With an impressive impact factor and ranking in the top quartile (Q1) of its classifications, the journal is recognized for its rigorous peer-reviewed research and comprehensive reviews, aiming to advance the understanding of therapeutic interventions in gastrointestinal and liver diseases. Since its inception in 1987, it has become an essential resource for researchers, healthcare professionals, and students alike, fostering scientific dialogue and innovation. With a Scopus rank placing it in the 97th percentile for pharmacology and 96th for gastroenterology, it is dedicated to publishing the most significant and impactful findings in the field. ALIMENTARY PHARMACOLOGY & THERAPEUTICS thus plays a vital role in shaping the future of medical treatments and interventions in gastrointestinal health.

DERMATOLOGY, an esteemed journal published by KARGER, is a vital resource in the field of dermatological research and clinical practice. Established in 1893, with its comprehensive coverage extending to 2024, this journal has earned its place as a leading publication, holding a prestigious Q1 quartile ranking in Dermatology and ranking 15th out of 142 in the Scopus Medicine - Dermatology category, reflecting its 89th percentile standing within the discipline. The journal aims to disseminate innovative research findings, critical reviews, and clinical studies that advance the understanding of skin disorders and their treatments. While primarily available through institutional subscriptions, DERMATOLOGY remains committed to enhancing accessibility and fostering international collaboration among researchers, professionals, and students in the dermatological community. Its rigorous peer-review process guarantees the highest quality of published works, making it an essential reference for those dedicated to advancing dermatological science and improving patient care.

The Journal of Dermatological Science is a premier peer-reviewed publication dedicated to advancing knowledge in the field of dermatology, biochemistry, and molecular biology. Established in 1990 and published by Elsevier Ireland Ltd, this esteemed journal has consistently achieved high academic recognition, securing a Q1 ranking in Dermatology and a Q2 ranking in both Biochemistry and Molecular Biology as of 2023. With a notable impact factor and a Scopus rank that places it within the top tier of dermatology journals globally, it serves as a critical platform for researchers, clinicians, and academicians to disseminate their findings and foster innovation in skin health and disease management. Although the journal is not open access, it provides essential insights into cutting-edge research, clinical practices, and molecular mechanisms underlying dermatological conditions. The Journal of Dermatological Science is not only a vital resource for high-quality articles but also a driving force in shaping the future landscape of dermatological research.

Clinical Therapeutics, published by Elsevier, is a highly esteemed peer-reviewed journal that has been pivotal in advancing the field of pharmacology since its inception in 1977. With an impressive impact factor and recognition as Q2 in Pharmacology and Q1 in Medical Pharmacology for 2023, it stands at the forefront of research and discussions on innovative therapeutic strategies and pharmacological advancements. This journal not only caters to a broad audience of researchers and clinicians but also plays a vital role in disseminating critical information that supports the enhancement of patient care and safety. As a repository of high-quality, evidence-based articles, Clinical Therapeutics is a crucial resource for those involved in drug development, medical research, and clinical practice, making it an essential read for anyone dedicated to improving health outcomes through pharmaceutical sciences.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Pharmacogenomics & Personalized Medicine is a premier open-access journal published by DOVE MEDICAL PRESS LTD, focusing on the vital intersection of pharmacogenomics, pharmacology, and personalized approaches to medicine. Launched in 2008 and based in New Zealand, this journal plays an essential role in disseminating cutting-edge research that aims to enhance therapeutic efficacy through individualized treatment strategies. With its Q3 ranking in both Molecular Medicine and Pharmacology as of 2023, Pharmacogenomics & Personalized Medicine is gaining momentum in the scientific community, providing a platform for researchers to explore significant findings and their implications for patient care. The journal's commitment to open access ensures that valuable information is readily available to a global audience, promoting collaboration and innovation across various fields of health science. We invite researchers, professionals, and students to contribute and explore groundbreaking studies that pave the way for advancements in personalized healthcare.

Current Research in Translational Medicine, published by ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER, is a dynamic open-access journal that has been at the forefront of innovative research since its inception in 2016. With a strong commitment to advancing the fields of biochemistry, hematology, infectious diseases, oncology, and transplantation, the journal provides an invaluable platform for researchers and practitioners to share novel findings that bridge laboratory discoveries and clinical applications. Currently recognized in prestigious categories such as Q1 and Q2 quartiles, this journal emphasizes the importance of translational science in improving health outcomes, supported by a rigorous editorial process and a commitment to high-quality research dissemination. Being listed in reputable databases like Scopus, it enables authors to reach a wide audience, ensuring that their impactful work contributes to the global dialogue on critical medical advancements. With its open access model, Current Research in Translational Medicine encourages widespread collaboration and engagement among the scientific community, solidifying its role as a leading journal in medicine and related fields.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

International Journal of Molecular Medicine is a prestigious publication dedicated to advancing the field of molecular medicine through innovative research and scholarly dialogue. Published by Spandidos Publications Ltd in Greece, this journal has successfully provided a platform for academics and professionals alike since its inception in 1998. With an impressive 2023 Q1 ranking in Medicine (Miscellaneous) and a Q2 ranking in Genetics, the journal maintains a vital role in disseminating high-quality research, underscored by its strong performance in the Scopus rankings, particularly in the realm of genetics where it ranks 28 out of 347. Researchers will benefit from its comprehensive scope, which encompasses a wide range of topics within molecular biology, genetics, and their clinical applications. Although the journal does not operate under an open access model, it remains influential, providing critical insights that contribute significantly to the understanding and development of molecular therapeutic strategies and innovations.